MAML2 and neoplasm: Since p16 loss is an independent genetic alteration concurrent with the CRTC1-MAML2 fusion in human MEC (Figure 4H), it suggests that the deregulation of p16-CDK4/6-RB is needed to further abrogate the cell cycle control and confer tumor aggressiveness.